University of Vermont Medical Center
Trial Pipeline
Nutritional Prehabilitation to Improve Cancer Outcomes (N-PICO)
NCT07072377
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
NCT06778408
Optimizing Aerobic Fitness in Older Adults
NCT06951620
Avocado and Postprandial Responses
NCT06818032
Multi-disciplinary Care for Brain Metastases
NCT06280300
Care Coordination Educational Intervention Study for Patients from Rural Areas with Early Stage Cancer
NCT05723250
Venous Thromboembolism Prevention in Outpatients With Glioma
NCT05683808
Remote Smoking Cessation in Hospitalized Cardiac Patients
NCT05738408
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
NCT05603715
Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy
NCT02110667
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 58 |
What the Pipeline for University of Vermont Medical Center Shows
According to the ClinicalTrials.gov registry, University of Vermont Medical Center is linked to 119 US clinical trials across every stage of research activity. Of those, 118 studies are currently recruiting — about 99% of the sponsor's indexed portfolio — and 1 are already marked complete, representing roughly 1% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Vermont Medical Center reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 58 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Vermont Medical Center is Post-Prostatectomy with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.